Welcome to the 9th Microbiome Movement Drug Development Summit

As landmark Ferring & Seres Therapeutics approvals proved the safety of the microbiome modality, robust clinical efficacy data for disease areas beyond infectious were paramount to reinvigorate investment across the community.

The 9th Microbiome Movement Drug Development Summit returned as the industry’s trusted, definitive forum for the global network of microbial therapeutic developers. It ensured teams, like those joining from Enterobiotix, Freya Biosciences & Genome & Co could stay ahead of the curve to robustly prove clinical efficacy as regulator and investor scrutiny necessitated more compelling data than ever before.

This was the attendees' only meeting dedicated to supporting business-critical networking, featuring a start-up showcase that supported the biotech industry to secure funding and progress preclinical pipelines. This was an unmissable touchpoint for developers to gain insights from live biotherapeutic and small molecule pipelines generating robust data in the clinic and improve their navigation of a fast-evolving market landscape.

Across 2 conference days, with Translational, Clinical & Manufacturing tracks, a new interactive poster session and an additional pre-conference workshop day designed for innovation scouting, strategic portfolio planning and networking with investors, C-Level, R&D, CMC and Investor stakeholders joined, as 150+ innovators and thought-leaders gathered under the common goal to prove the power of microbiome-altering modalities!

They were part of the industry’s premier platform for connection-building in 2024 - Concerto Biosciences, Altimmune & Exegi Pharmaceuticals joined to shape the future direction of the microbiome-altering therapeutics field – Were you?